Tesa+IP5

Tesamorelin–ipamorelin two-component research blend · “IP5” shorthand is not inositol pentaphosphate

Component- and lot-specific; require identity, individual purity/content results and measured blend ratio · target, verify batch COACAS 218949-48-5RUO

Research statusComponent-level literature exists; the combined formulation has no approval or qualifying controlled clinical co-administration study

Supplied formTwo-component peptide blend: 44-residue hexenoylated GHRF analogue plus synthetic pentapeptide secretagogue

Lead timeConfirmed with quote

Tesa+IP5 — Lot-specific lyophilized blend; confirm physical form and component ratio on the released-batch COA

Tesa+IP5 — Lot-specific lyophilized blend; confirm physical form and component ratio on the released-batch COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Defensible research value includes dual-pathway GH-axis model design, receptor-selective controls, component-resolved analytics, mixture stability and comparison with each component alone
Component monotherapy evidence does not establish synergistic efficacy, visceral-fat reduction, body recomposition, sleep, recovery or metabolic benefit for the combined blend.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: 218949-48-5
Formula: Multi-component blend; C₂₂₁H₃₆₆N₇₂O₆₇S (tesamorelin free base) and C₃₈H₄₉N₉O₅ (ipamorelin)
Molecular weight: Component-specific; no single molecular weight
Appearance: Lot-specific lyophilized blend; confirm physical form and component ratio on the released-batch COA
Purity: Component- and lot-specific; require identity, individual purity/content results and measured blend ratio · target, verify batch COA
Storage: Follow the blend’s released-lot label, COA and stability data. Do not transfer EGRIFTA SV or WR reconstitution and in-use instructions, or vendor ipamorelin timelines, to a different two-component lyophilized matrix.
MOQ: On request
Lead time: Confirmed with quote

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Tesa+IP5

This catalogue item is a two-component research blend of tesamorelin, a modified GHRH analogue, and ipamorelin, a pentapeptide GHS-R1a agonist. “IP5” is catalogue shorthand for the ipamorelin component and must not be interpreted as inositol pentaphosphate; the previous phytic-acid article and structure were unrelated and have been removed. FDA approval applies to named tesamorelin finished drugs, not bulk tesamorelin, ipamorelin or this blend. No qualifying controlled clinical study of the combination was identified.

Appropriate laboratory contexts include GHRH-receptor and GHS-R1a signalling, dual-pathway model design, component interaction experiments with single-agent controls, blend identity and ratio methods, stability and container studies
No approved clinical indication applies to this combination.

Mechanism context

The question the literature is testing

Tesamorelin engages the GHRH receptor, while ipamorelin engages GHS-R1a. Convergence on somatotroph signalling provides a testable laboratory hypothesis, not proof of additive or synergistic human benefit. Experiments require single-component controls, authenticated materials, confirmed concentrations and component-resolved readouts; component pharmacokinetics cannot be merged into one blend half-life or schedule.

Evidence map

Research routes and exposure context

Evidence tierHuman clinical research

Research areaGrowth-hormone axis research

Routes reported in sources

No administration route applies

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary administration
Tesamorelin finished-drug warnings do not establish safety of ipamorelin or the blend, and controlled combination safety data were not identified
FDA states that compounded ipamorelin acetate may pose immunogenicity risk for certain routes because of aggregation or peptide-related impurities; its unnatural amino acids also increase characterization complexity
FDA additionally identified serious adverse events, including death, in literature involving intravenous ipamorelin for gastric motility, while noting insufficient information for some other injectable routes
These findings must remain tied to that compounded-drug and route context; they do not qualify or condemn a specific released research lot
Incorrect ratio, identity or content, aggregation, degradation, contamination and unvalidated endotoxin or sterility are material risks
Both GH-axis components fall within current WADA prohibited classes.

Interactions reported in the literature

No human combination guidance applies
Additional GH, secretagogues, peptides, insulin or glucocorticoid advice was removed
Laboratory interaction studies must define each component, use dose matrices and single-agent controls, and monitor component-resolved and downstream readouts without assuming clinical compatibility.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Tesa+IP5 factory batch COAs

No factory batch COA is published for this product yet. Ask sales for the latest available document.

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require full identity and modification for each peptide, intact mass and peptide mapping where appropriate, individual chromatographic purity and quantitative content, salt and counterion basis, target and measured blend ratio, water, residual solvents, related peptides, aggregation or particulates where relevant, container integrity and blend-specific stability
Physiological response or appearance cannot qualify identity or potency.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

TESAIPA-15MG15 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the blend’s released-lot label, COA and stability data. Do not transfer EGRIFTA SV or WR reconstitution and in-use instructions, or vendor ipamorelin timelines, to a different two-component lyophilized matrix.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Primary component references include the current FDA EGRIFTA WR label for the named tesamorelin finished product; NIH PubChem CIDs 16137828 and 9831659; peer-reviewed ipamorelin studies including PMID 10496658 and PMID 25331030; FDA's current compounding-risk page and October 2024 PCAC materials; and the official WADA 2026 Prohibited List. These sources do not constitute evidence for co-administration or the blend. The previous inositol-pentaphosphate/phytic-acid reference was unrelated to this product identity and was removed.

01
Metabolic effects of a growth hormone-releasing factor in patients with HIV
New England Journal of Medicine · 2007 · peer-reviewed original research (Phase 3 randomized controlled trial)
Open source
02
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data
Journal of Clinical Endocrinology & Metabolism · 2010 · peer-reviewed original research (pooled analysis of two pivotal Phase 3 RCTs)
Open source
03
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
JAMA · 2014 · peer-reviewed original research (randomized controlled trial)
Open source
04
Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
Lancet HIV · 2019 · peer-reviewed original research (randomized controlled trial)
Open source
05
Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial
Archives of Neurology · 2012 · peer-reviewed original research (randomized controlled trial)
Open source
06
Ipamorelin, the first selective growth hormone secretagogue
European Journal of Endocrinology · 1998 · peer-reviewed original research (preclinical/early clinical pharmacology)
Open source
07
Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients
International Journal of Colorectal Disease · 2014 · peer-reviewed original research (Phase 2 multicenter randomized controlled trial)
Open source
08
Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a
Proceedings of the National Academy of Sciences of the United States of America (PNAS) · 2008 · peer-reviewed original research (basic/mechanistic pharmacology)
Open source

Product FAQ

Questions buyers ask about Tesa+IP5

What does “IP5” mean in this catalogue name?+

In this record it is shorthand associated with the ipamorelin component, not inositol pentaphosphate or phytic acid. Shorthand is not a chemical identity or guaranteed fill amount. The quotation, label and released-lot COA must spell out tesamorelin and ipamorelin and state the target and measured amount of each.

What must the batch COA state for a tesamorelin–ipamorelin blend?+

Require identity, sequence and modification, salt or counterion basis, theoretical and measured mass, individual purity, quantitative content and acceptance result for each peptide, plus target and measured component ratio. A single HPLC purity value or total vial fill cannot prove both peptides are present at the claimed amounts.

Does FDA approval of EGRIFTA qualify this blend or its storage?+

No. Approval and storage instructions apply to the named EGRIFTA finished formulation, strength, excipients, manufacturing controls and label. They do not transfer to bulk tesamorelin, ipamorelin or a combined vial. Use blend-specific released-lot stability data and independently qualify solvent, concentration, container, temperature and hold time for any solution work.

Tesa+IP5

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Tesa+IP5

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Tesa+IP5 factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial

Ipamorelin, the first selective growth hormone secretagogue

Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a

Questions buyers ask about Tesa+IP5

Compare adjacent molecules and documentation needs.

Tesamorelin

Ipamorelin

Sermorelin

GHRP-2